Key Points
-
Hims & Hers Health drives growth via its subscription-based wellness platform targeting specific consumer conditions.
-
Teladoc Health maintains a leading position with over 100 million global members and extensive institutional partnerships.
-
Both companies represent distinct strategies in digital healthcare, offering unique risk-reward profiles for 2026 investors.
As virtual care reshapes the healthcare landscape, the investment decision between Hims & Hers Health (NYSE:HIMS) and Teladoc Health (NYSE:TDOC) hinges on whether investors prioritize high-growth consumer subscription models or established large-scale institutional platforms.
Hims & Hers specializes in direct-to-consumer wellness solutions for conditions like hair loss and weight management. Teladoc offers a comprehensive virtual care ecosystem for employers and health plans. While both lead in digital health innovation, their approaches to market expansion and profitability present contrasting investment opportunities.
The Case for Hims & Hers Health
Hims & Hers operates a direct-to-consumer digital health platform focused on personalized treatments for hair care, mental health, and weight management. Serving nearly 2.6 million subscribers as of Q1 2026, the company is scaling through its pending acquisition of Eucalyptus while securing a $400 million receivables facility with JPMorgan Chase (NYSE:JPM) to bolster pharmacy operations.
In FY 2025, the company generated revenue of approximately $2.3 billion, reflecting a 59% year-over-year growth. It achieved net income of nearly $128.4 million, with a net margin of roughly 5.5%. Its debt-to-equity ratio of 2.1x suggests higher leverage, though its current ratio of 1.9x indicates adequate short-term liquidity.
The Case for Teladoc Health
Teladoc serves over 100 million members globally via its Integrated Care and BetterHelp platforms, recently expanding through a partnership with Walmart (NASDAQ:WMT) to embed virtual care into retail channels. However, its top five clients historically account for nearly 19% of revenue, creating dependency risks.
During FY 2025, Teladoc reported revenue of about $2.5 billion, a 1.5% decline from the prior year, while narrowing its net loss to $200.3 million (down from $1.0 billion). The company’s debt-to-equity ratio of 0.8x signals conservative leverage, with a strong current ratio of 2.7x for liquidity.
Risk Profile Comparison
Hims & Hers faces regulatory challenges around compounded GLP-1 medications and peptides, with potential FDA restrictions and ongoing DOJ/HHS investigations. Rapid integration of acquisitions like Eucalyptus also introduces operational risks that could disrupt growth.
Teladoc’s risks stem from heavy client concentration and stagnation in BetterHelp user growth. Intense competition from tech giants such as Amazon (NASDAQ:AMZN) and Alphabet, (NASDAQ:GOOG) (NASDAQ:GOOGL) further complicates its path to profitability.
Valuation Comparison
Teladoc Health trades at a lower price-to-sales ratio compared to Hims & Hers, which carries a higher forward price-to-earnings ratio amid its rapid growth. Metrics are benchmarked against the SPDR XLV sector ETF.
| Metric | Hims & Hers Health | Teladoc Health | Sector Benchmark |
|---|---|---|---|
| Forward P/E | 78.9x | 59.4x | 389.1x |
| P/S ratio | 3.5x | 0.7x | – |
Valuation metrics sourced from Financial Modeling Prep (FMP).
Which Stock for 2026 Investors?
Investors face a choice between Hims & Hers’ consumer-focused subscription model and Teladoc’s institutional platform approach. Hims & Hers targets recurring health needs, including sexual health and weight loss, with strong revenue predictability. Teladoc’s strategy centers on employer and health plan contracts, though it has struggled post-pandemic amid Livongo acquisition costs and BetterHelp user declines.
While Hims & Hers commands a premium valuation amid regulatory risks, its growth trajectory remains steady. Teladoc’s lower valuation and turnaround efforts may appeal to value-focused investors, though execution risks persist. Based on growth sustainability and strategic clarity, Hims & Hers emerges as the more compelling long-term opportunity.